Home > Insider Trading > Filing (0000899243-17-025510)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701108	Spero Therapeutics Inc.	SPRO	()	MA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1030575	Francois Jean Formela	C/O Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14Th Floor Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-06	245,605	$0.00	288,386	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	246,272	$0.00	534,658	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	328,992	$0.00	863,650	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	513,318	$0.00	1,376,968	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	602,589	$0.00	1,979,557	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-06	428,571	$14.00	2,408,128	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Junior Preferred Stock	Disposition	2017-11-06	1,492,645	$0.00	245,605	$0.00
Common Stock	Series A Preferred Stock	Disposition	2017-11-06	982,906	$0.00	246,272	$0.00
Common Stock	Series B Preferred Stock	Disposition	2017-11-06	1,250,000	$0.00	328,992	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-11-06	3,119,633	$0.00	513,318	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-11-06	3,662,178	$0.00	602,589	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Reflects shares of the Issuer's common stock that were purchased in connection with the Issuer's initial public offering.
Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). Each series of preferred stock was automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
Shares held by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Formela is a member of AVA X LLC and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.